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Background: An accurate evaluation of neoadjuvant treatment is important to maxi-
mize the prognostic benefit of this strategy in each individual patient. The main aim 
of the present study is to investigate the difference between carbohydrate antigen 
19-9 and fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) 
in evaluating the response to neoadjuvant treatment for resectable and borderline 
resectable pancreatic ductal adenocarcinoma (PDAC) patients.
Methods: Pancreatic ductal adenocarcinoma patients with positive standard uptake 
values (SUV) on FDG-PET before neoadjuvant chemoradiotherapy (NACRT) were 
enrolled (n = 141). In all patients, CA19-9 and FDG-PET were evaluated before the 
initiation of and after the completion of NACRT. The statuses of CA19-9 and FDG up-
take alterations during NACRT were assessed in association with survival and tumor 
recurrence profiles.
Results: A favorable response in each CA19-9 and FDG-PET was significantly re-
lated to better survival, respectively, than the unfavorable response (44.3% vs 19.5%, 
P < .001 and 45.8% vs 24.6%, P < .001). The status of CA19-9 was significantly as-
sociated with the incidence of distant recurrence whereas the status of FDG-PET 
was significantly associated with the incidence of local recurrence, and only patients 
with a favorable response in both CA19-9 and PET statuses showed a significantly 
better survival than the others (5-year survival: 56% vs 24%, P < .001), and those with 
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1  | INTRODUC TION
A trend toward a multidisciplinary treatment strategy is emerging 
in various malignant diseases. Neoadjuvant treatment with subse-
quent surgery for pancreatic ductal adenocarcinoma (PDAC) is being 
actively investigated, with reported favorable survival (5-year sur-
vival rates of 36% to 53%).1-3 One theoretical advantage of a neo-
adjuvant treatment strategy for PDAC is accurate identification of 
patients with unresectable factors who are unlikely to benefit from 
surgery.4,5 However, a substantial number of patients still experi-
enced postoperative tumor recurrence after subsequent surgery.1,6,7 
For this reason, maximizing the therapeutic benefit of neoadjuvant 
treatment for each individual patient requires meticulous discrimi-
nation of who would truly benefit from the subsequent surgery and 
who would not.
Carbohydrate antigen 19-9 (CA19-9) is the most widely used 
serum marker for PDAC detection. Preoperative serum CA19-9 is 
positively associated with tumor burden and serum CA19-9 levels 
are prognostic in pancreatic cancer.8 In addition, changes in serum 
CA19-9 during preoperative treatment are reported to be useful in-
dicators of treatment response. In particular, many previous reports 
have suggested that normalization of CA19-9 during preoperative 
treatment is a robust, significant predictor of improved survival after 
subsequent resection, reflecting a favorable treatment response 
and significantly reduced tumor burden.9-11 However, even with suc-
cessful CA19-9 normalization during preoperative treatment, 5-year 
survival remains approximately 50%;9-12 hence, a single evaluation 
of successful CA19-9 normalization after preoperative treatment 
remains unsatisfactory for identifying optimal candidates for subse-
quent pancreatectomy.
Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomog-
raphy (PET)/ computed tomography (CT) is a functional imaging mo-
dality that can detect changes in tissue metabolism. Carbohydrate 
metabolism is more active in malignant cells, resulting in significant 
accumulation of FDG.13 FDG-PET/CT has been thoroughly investi-
gated in esophageal, rectal, and other cancers for detecting residual 
viable cancer or response after anticancer treatment.14,15 An early 
decrease in FDG uptake in the primary tumor during preoperative 
therapy can predict not only the pathological response but also sur-
vival among patients with esophageal or breast cancer, among oth-
ers.16,17 We previously reported that a change in FDG uptake during 
neoadjuvant chemoradiotherapy (NACRT) is significantly associated 
with surgical outcomes among patients with PDAC.18 Our findings 
indicated that a > 50% decrease in the maximum standard uptake 
value (SUV-max) during preoperative chemoradiotherapy (CRT) is 
significantly related to favorable outcomes after radical resection, 
reflecting a favorable response to neoadjuvant treatment and signif-
icant attenuation of locoregional tumor activity.
These observations may indicate that FDG uptake evaluation as-
sesses a different aspect of tumor pathophysiology and response 
to neoadjuvant treatment from the CA19-9 evaluation. In this 
context, assessment of the response per FDG-PET in combination 
with CA19-9 evaluation might enhance the prognostic significance 
of CA19-9 changes in patients with PDAC treated preoperatively; 
however, evidence for this effect is scarce. Truty et al assessed the 
significance of CA19-9 alterations and pathological response of the 
resected specimen in patients with unresectable and borderline re-
sectable pancreatic cancer receiving neoadjuvant chemotherapy. 
In their patient population, FDG-PET alterations were highly cor-
related with pathological response,19 but these authors could eval-
uate changes in FDG uptake during preoperative treatment in only 
67 (35%) of 194 patients enrolled. In addition, they found no addi-
tional impact of FDG-PET in predicting surgical outcome, primarily 
because of the small number of patients for whom information about 
preoperative FDG changes was available.
In the current two-center study of 141 patients with resectable 
and borderline resectable PDAC, we examined the prognostic sig-
nificance of changes in CA19-9 and in FDG uptake during preoper-
ative treatment. In addition to evaluating the association of these 
two predictive factors with response to neoadjuvant treatment for 
PDAC, we investigated any further predictive significance of FDG-




Between 2008 and 2016, a total of 401 patients with pancreatic can-
cer received NACRT at Osaka International Cancer Institute (OICI) or 
Osaka University Hospital (OUH). Either histological or cytological 
unfavorable response in either of CA19-9 or PET status showed similar poor survival 
to those with unfavorable in both (P = .164).
Conclusion: CA19-9 and PET evaluation provided oncologically different risk assess-
ments in terms of tumor recurrence profile, and favorable response in both CA19-9 
and FDG-PET were necessary to achieve prognostic benefit from NACRT.
K E Y W O R D S
CA19-9, chemoradiotherapy, FDG-PET, neoadjuvant, pancreatic cancer
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evidence of adenocarcinoma of the pancreas was obtained before 
initiation of preoperative treatment. Of this group, 32 patients did 
not undergo radical surgery after NACRT mainly because of the 
detection of distant metastasis, and FDG-PET was not carried out 
before NACRT in 101 patients although they underwent radical sur-
gery; all of these patients were excluded from this study. Another 65 
patients with a negative FDG-PET SUV before NACRT and 62 who 
did not receive FDG-PET after NACRT were also excluded. Patients 
additionally were excluded if they had pancreatitis, cholangitis, or 
uncontrolled diabetes before the preoperative treatment. Finally, a 
total of 141 patients with PDAC-R (n = 102) or PDAC-BR (n = 39), 
according to NCCN guideline Ver. 2.2018 resectability criteria, were 
enrolled in the study (Figure S1).
All patients underwent FDG-PET/CT using the same protocol 
before NACRT initiation and after its completion but before surgical 
laparotomy (ie, at least 3 weeks after completion of the radiation 
component). They also all had routine radiographic imaging, such as 
CT, magnetic resonance imaging (MRI), and endoscopic ultrasonog-
raphy (EUS). Serum CA19-9 was examined before and after NACRT. 
All patients were followed until disease recurrence and/or death with 
a median follow-up period of 31.0 months (range, 4.9-112.9 months).
2.2 | Preoperative chemoradiation therapy
Patients received preoperative CRT according to the regimen of 
a prospective phase II clinical trial in each hospital (UMIN-CTR: 
UMIN000037142). Written informed consent was granted under an 
approved procedure. Details of the regimens for NACRT have been 
described previously.6,20 Briefly, three-dimensional radiation was 
targeted to the following fields, given at a total dose of 40-60 Gy 
with a daily fraction of 1.8-2.0 Gy for 5 days/week: the primary pan-
creatic tumor, celiac and superior mesenteric arteries, retroperito-
neal soft tissue, and para-aortic region. The gastrointestinal tract, 
including the stomach and duodenum, was excluded from the field of 
irradiation. At OICI, gemcitabine alone was given with radiotherapy; 
i.v. gemcitabine (1000 mg/m2) was initiated concurrently on days 1, 
8, and 15 during each 4-week cycle for three cycles. This preopera-
tive CRT was completed within 3 months.6 In OUH, gemcitabine and 
S-1 were given with radiotherapy; i.v. gemcitabine (1000 mg/m2) was 
initiated concurrently on days 1 and 8 and S-1 orally on days 1-5 and 
8-12 during each 3-week cycle for two cycles. This preoperative CRT 
was completed within 2 months.20 The pathological response of the 
primary pancreatic tumor to preoperative CRT was evaluated using 
the histological grading schema described by Evans et al.21
2.3 | Protocol for FDG-PET/CT
Whole-body FDG-PET/CT was carried out using the Gemini GXL 
(Phillips, Eindhoven, the Netherlands) or Biograph Duo (Siemens, 
Munich, Germany). Prior to imaging, all patients fasted for 5 hours 
before i.v. administration of FDG at a dose of 3.7 MBq/kg weight 
(mean dose 200 MBq). Whole-body PET/CT images were acquired 
120 minutes after FDG administration. SUV-max was calculated for 
the primary pancreatic tumor. The SUV-max obtained before initiat-
ing preoperative CRT was defined as the pre-CRT SUV, and the SUV-
max obtained after completion of preoperative CRT was defined as 
the post-CRT SUV. The decrease ratio of SUV-max was defined as 
follows; decrease ratio = (1 – post-CRT SUV/pre-CRT SUV) × 100. 
In this study, the SUV-max of the tumor before initiating CRT was 
positive in all patients.
2.4 | Statistical analysis and ethical concerns
All data are expressed as mean ± standard deviation or median and 
range. Differences in continuous values were evaluated using the 
Student’ t test or Mann-Whitney U test. Categorical data were com-
pared using Fisher’s exact probability test or Pearson’s chi-squared 
test, as appropriate. Overall survival rates were estimated using the 
Kaplan-Meier method and compared by log-rank test. To analyze 
independent prognostic factors, we used a Cox proportional haz-
ards regression model with stepwise comparisons. All analyses were 
carried out in IBM SPSS statistics version 21.0 (IBM Japan Business 
Logistics), and P < .05 was considered significant. The statistical ex-
pert in our laboratory performed all statistical analyses.
The study protocol was approved by the Human Ethics Review 
Committee of Osaka International Cancer Institute and Osaka 




Patient characteristics are summarized in Table 1. Most patients had 
R0 resection, but one patient had an R1 resection (residual micro-
scopic cancer). The pathological T factor (pT) from the UICC-TNM 
classification, 7th edition, was determined in patients with patho-
logically complete response (pCR), and pT1, pT2, pT3, or lymph node 
metastasis was observed in 40 patients (28.4%). The 5-year survival 
rate for the complete cohort was 34.1%, and recurrence was ob-
served in 85 patients. We found no difference between the OICI and 
OHU groups for gender, tumor location, resectability status, CA19-9 
level, or SUV-max before NACRT, but the groups did differ for age, 
chemotherapy regimen, total irradiation dose, and rate of recurrence 
(data not shown).
3.2 | Prognostic significance of CA19-9 status and 
FDG-PET after NACRT
Median CA19-9 value after NACRT was 31.0 (0.0-16 460) U/mL, 
which was significantly lower than the CA19-9 value before NACRT 
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(165.0 [0-14 795] U/mL; P < .001, Figure S2A). We divided the pa-
tients into two groups: those with normalized CA19-9 (≤37 U/mL) 
after NACRT (potentially normalized CA19-9 group, n = 82) and 
those without CA19-9 normalization after NACRT (CA19-9–el-
evated group, n = 59). The 82 patients in the potentially normalized 
CA19-9 group were further analyzed as two subgroups; those with 
elevated CA19-9 (>37 U/mL) before NACRT and normalized CA19-9 
(≤37 U/mL) after NACRT (true normalized CA19-9 group, n = 46) 
and those with negative CA19-9 (≤37 U/mL) before NACRT (nega-
tive CA19-9 group, n = 36). Because survival in the negative CA19-9 
group did not differ significantly from that of the other CA19-9 
group (Figure S3), we defined the 82 patients with CA19-9 < 37 U/
mL after NACRT as CA19-9 good responders and the remaining 59 
patients in the CA19-9–elevated group as CA19-9 poor responders. 
Figure 1 shows disease-free and overall survival curves. The 5-year 
disease-free survival rate among CA19-9 good responders was 
49.5%, which was significantly higher than in the poor responders 
subgroup (17.2%, P < .001; Figure 1A). The 5-year overall survival 
rate was 44.3% among the CA19-9 good responders, which was also 
significantly higher than among poor responders (19.5%, P < .001; 
Figure 1B).
Average SUV-max was significantly lower after NACRT 
(2.55 ± 1.29) than before NACRT (5.41 ± 3.62, P < .001; Figure S2B). 
Based on our previous study, we defined patients whose decrease 
ratio of SUV-max was ≥ 50% as PET good responders, and patients 
with a < 50% decrease ratio as PET poor responders.18 Figure 1C,D 
shows the survival curve for each group, indicating that PET good 
responders had a significantly better prognosis than the poor re-
sponder group for both disease-free and overall survival (5-year 
disease-free survival rate: 48.5% vs 26.6%, P = .001; 5-year overall 
survival rate: 45.8% vs 24.6%, P < .001).
In the 82 patients in the CA19-9 good responder subgroup, 45 
were PET good responders, and 37 were PET poor responders. The 
latter had significantly worse survival compared to those in the PET 
good responder group, despite also being in the CA19-9 good re-
sponder subgroup (Figure 2). These findings indicated the additional 
prognostic significance of PET status added to CA19-9 status in the 
evaluation of NACRT response.
3.3 | Relationship between CA19-9/PET status and 
patterns of recurrence
Figure 3A,B shows the cumulative incidence of distant and local re-
currence according to CA19-9 status. As shown in Figure 3A, the 
CA19-9 good responder subgroup had a significantly lower inci-
dence of distant recurrence, without a significant difference in local 
site recurrence between the CA19-9 good and poor responders 
(Figure 3B). This result indicated that an absence of CA19-9 normali-
zation after NACRT suggests a residual systemic tumor burden after 
preoperative treatment and subsequent surgery.
Figure 3C,D shows the pattern of recurrence according to PET 
status. In contrast to CA19-9 status, PET good responders had a sig-
nificantly lower incidence of local and distant recurrence compared 
to PET poor responders (Figure 3C,D). These observations indicated 
that an unfavorable PET status may indicate a more aggressive tumor 
biology and resistance to NACRT in local and systemic diseases.
3.4 | Relationship between CA19-9/PET status and 
histological response and nodal status
For this part of the analysis, we divided patients into histological poor 
responders, grade I/IIA (n = 79), and histological good responders, 
grade IIA/III/IV (n = 62), based on histological response per Evans 
et al21. As shown in Table 2, PET status was significantly related to 
histological response status (P = .003), but CA19-9 status was not 
(P = .175). PET and CA19-9 status both showed significant associa-
tions with lymph node status (P = .021 and 0.002, respectively), with 
CA19-9 status showing the stronger association (Table 2).
3.5 | Prognostic impact of combining CA19-9 
status and SUV-max (combination status)
Of the 141 patients enrolled in this study, 45 were classified as both 
CA19-9 and PET good responders, 37 as CA19-9 good respond-
ers but PET poor responders, 19 as CA19-9 poor responders and 
PET good responders, and the remaining 40 as poor responders for 
TA B L E  1   Characteristics of enrolled patients
Total (n = 141)
Institute (OICI/OUH) 83/58
Age (years) 67.5 ± 9.1
Gender (male/female) 87/54
Tumor location (head/body-tail) 83/58
Tumor size (mm) 24.6 ± 9.6
Resectability status (Resectable/Borderline 
resectable)
102/39
CA19-9 (U/mL) 165 (0-14 795)
SUV-max 5.41 ± 3.62
Chemotherapy (Gem/Gem + S-1) 101/40
Irradiation dose (Gy) (40/50/60) 14/58/69
Operation (PD/DP/TP) 80/56/5




Evans classification (I/IIA/IIB/III/IV) 14/65/45/13/4
Recurrence (no/yes) 56/85
Abbreviations: DP, distal pancreatectomy; OICI, Osaka International 
Cancer Institute; OUH, Osaka University Hospital; PD, 
pancreatoduodenectomy; SUV, standard uptake value; TP, total 
pancreatectomy.
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both CA19-9 and PET. As shown in Figure 4A, the group of good re-
sponders on both measures had better survival than the other three 
groups, with a 5-year survival rate of 56.0%, which was significantly 
higher than the other groups combined (23.8%, P < .001; Figure 4B).
On univariate analysis, tumor size before NACRT, tumor size 
after NACRT, CA19-9 value before NACRT, CA19-9 value after 
NACRT, combination status, and resectability status were significant 
prognostic factors (Table 3). On multivariate analysis using these six 
factors, however, only the combination status and resectability sta-
tus were independent prognostic factors, with the combination sta-
tus emerging as the more powerful of the two (Table 3).
4  | DISCUSSION
An appropriate evaluation of the response to neoadjuvant treatment 
and accurate identification of optimal candidates for subsequent sur-
gery are key to improving outcomes for patients with PDAC treated 
using a neoadjuvant treatment strategy.7,22,23 Several approaches 
are possible for evaluating the response to neoadjuvant treatment 
before subsequent surgery. An alteration of tumor markers is a 
standard method in various malignant diseases, and increasing clini-
cal evidence highlights the prognostic implications of CA19-9 nor-
malization during this treatment for PDAC, as shown in the current 
study.9-12 We also found that changes in FDG uptake during neoad-
juvant treatment were significantly associated with pancreatectomy 
outcomes. More important, even in the CA19-9 good responders, 
an unfavorable PET status was associated with impaired survival. 
The 5-year survival was 44% in patients with a CA19-9 favorable 
status only (normalized CA19-9), but increased to 56% in patients 
who had good response based on both CA19-9 and PET. These find-
ings indicate an additional impact of PET status on CA19-9 measures 
in evaluating response to neoadjuvant treatment. Evaluation of the 
combination status allowed for more accurate identification of pa-
tients who would likely benefit from the subsequent surgery.
We also note that only patients with a favorable response in 
terms of both CA19-9 (normalization) and PET status (>50% de-
crease in SUV-max) after NACRT gained the optimal prognostic ben-
efit from our treatment strategy. Survival of patients with favorable 
status for only one of these measures was not significantly improved 
F I G U R E  1   Disease-free survival (A) and overall survival (B) of CA19-9 good responder group (patients with CA19-9 normalization after 
NACRT, n = 82) were significantly better than those of CA19-9 poor responder group (patients without CA19-9 normalization after NACRT, 
n = 59). Disease-free survival (C) and overall survival (D) of PET good responder group (patients with > 50% SUV-max decrease after NACRT, 
n = 64) were significantly better than those of SUV-max poor responder group (patients with < 50% SUV-max decrease, n = 77)
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F I G U R E  2   In the 82 patients in the CA19-9 good responder subgroup, 45 were PET good responders, and 37 were PET poor responders. 
The latter had significantly worse disease-free survival (A) and overall survival (B) compared to those in the PET good responder group, 
despite also being in the CA19-9 good responder subgroup
F I G U R E  3   CA19-9 good responders had a significantly lower incidence of distant recurrence, without a significant difference in local 
site recurrence between the CA19-9 good and poor responders (A, B). PET good responders had a significantly lower incidence of local and 
distant recurrence compared to PET poor responders (C, D)
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compared to having an unfavorable status on both. Although an 
unfavorable status for either CA19-9 or PET after NACRT does not 
necessarily preclude surgical intervention, care is necessary for 
proceeding to surgery because these patients are at high risk for 
early tumor recurrence after pancreatectomy. Thus, patients with-
out a favorable response per CA19-9 or PET status might fare bet-
ter with additional chemotherapy using more effective agents (eg, 
FOLFIRINOX and Gem+nab-PTX) and re-evaluation of CA19-9 and 
PET status instead of immediate radical surgery after NACRT.24,25
We also carried out a detailed comparative analysis regarding 
patterns of recurrence according to CA19-9 and PET status. Our re-
sults showed that an unfavorable status on CA19-9 and PET was 
associated with different profiles of tumor recurrence depending on 
whether it involved one of the measures alone or both. For identi-
fying patients at high risk for local recurrence, FDG-PET was more 
useful than CA19-9 in our patient group. FDG-PET is a functional 
imaging modality that can detect changes in tissue metabolism, 
and FDG uptake is strongly associated with tumor aggressiveness. 
Yamamoto et al reported that a high SUV (SUV-max ≥ 6.0) was sig-
nificantly associated with microscopic locoregional tumor extension 
in PDAC and that survival after resection with high SUV was notably 
poor.26 This observation indicated a profound local aggressiveness 
of high SUV PDAC, which is in agreement with our findings of a sig-
nificant association of an insufficient decrease in FDG uptake with 
impaired histological response and unfavorable local control.
In identifying patients at high risk for distant recurrence, 
CA19-9 status was more significant than PET status, although an 
unfavorable status with either was associated with a higher inci-
dence of distant recurrence. Previous reports indicated that a lack 
of CA19-9 normalization after pancreatectomy is significantly as-
sociated with distant metastasis in a surgery-first approach for 
PDAC.27 Motoi et al found a significantly higher incidence of liver 
metastasis in patients with sustained elevation of postoperative 
CA19-9 compared to those with normalized postoperative CA19-
9.27 Our findings of a significantly high risk for distant recurrence in 
patients without normalized CA19-9 after presurgical neoadjuvant 
treatment can be considered a counterpart of these previous re-
sults in the surgery-first approach. Certainly, it is not surprising that 
TA B L E  2   Relationship between each status and pathological 
findings








Good (n = 64) 37/27 .003 52/12 .021
Poor (n = 77) 25/52 49/28
CA19-9 status
Good (n = 82) 40/42 .175 67/15 .002
Poor (n = 59) 22/37 34/25
Note: Evans classification good: Evans grade IIA/III/IV, Evans 
classification poor: Evans grade I/IIA. PET status good: Patients with 
a ≥ 50% decrease ratio of SUV-max after NACRT; PET status poor: 
Patients with a < 50% decrease ratio of SUV-max after NACRT; CA19-9 
status good: patients with normalized CA19-9 after NACRT; CA19-9 
status poor: patients without CA19-9 normalization after NACRT.
Abbreviation: LN, lymph node.
F I G U R E  4   The group of good responders on both CA19-9 and PET had better survival than the other three groups (P < .001) with a 
5-year survival rate of 56.0%, which was significantly higher than the other groups combined (23.8%, P < .001; B). In four groups according 
to the combination of CA19-9 and SUV-max status, only the CA19-9 good/PET good group (n = 45) showed a significantly better survival 
curve than the other three groups (A). The 5-year survival rate was 56.0% in the CA19-9 good/PET good group, which was significantly 
higher than that of the others (23.8%, P < .001)
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sustained elevation of CA19-9 after the eradication of locoregional 
tumor burden, such as with pancreatectomy or CRT, indicates the 
presence of occult systemic disease. In the setting of NACRT in this 
study, the improved eradication of local tumor burden because of 
CRT followed by pancreatectomy minimized the difference in local 
control regardless of CA19-9 status after NACRT. In this way, the 
difference in occult residual systemic tumor burden was maximized 
and became more evident for patients with normalized CA19-9 ver-
sus those without.
The current study has several limitations. First, it is retrospec-
tive, so significant selection bias was inevitable. Furthermore, the 
regimen of preoperative CRT differed between the two institutes, 
with a variety of chemotherapy agents and dose of irradiation, so the 
response to treatment and outcome after radical surgery could be 
different. In addition, the regimen of postoperative treatment was 
also different. In OICI, we usually performed liver perfusion chemo-
therapy (LPC) for the prevention of postoperative liver metastasis 
followed by systemic chemotherapy, whereas in OUH, only systemic 
chemotherapy was performed postoperatively. Certainly, the recur-
rence rate after radical surgery at OUH was significantly higher than 
at OICC, although the significance with CA19-9 and FDG-PET was 
similar at each institute, which adds strength to our results. Second, 
our conclusion is based on patients with PDAC receiving NACRT as 
preoperative therapy, and patients receiving neoadjuvant chemo-
therapy (NAC) were not included. Radiotherapy can have a strong 
locoregional anticancer effect, and we think that this effect might 
explain the relevance of PET status in adding to the prognostic sig-
nificance of CA19-9 status, which is a good indicator of systemic 
effect. Further analysis is necessary to evaluate the utility of FDG-
PET in combination with CA19-9 for the assessment of preoperative 
chemotherapy in PDAC patients.
In conclusion, we have identified the additional utility of FDG-
PET in combination with CA19-9 in evaluating the efficacy of NACRT 
for PDAC. An unfavorable CA19-9 status indicated a high risk for 
distant recurrence, and an unfavorable PET status was associated 
with a high risk for local recurrence. Neoadjuvant treatment efficacy 
was maximized only in patients with a favorable status with both 
CA19-9 and PET. The response evaluation of neoadjuvant treatment 
using multiple methods enables more accurate risk assessment for 
treatment failure and potentially contributes to the optimization of 
treatment strategy in each patient with PDAC.
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R E FE R E N C E S
 1. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, 
et al. Preoperative gemcitabine-based chemoradiation for patients 
Univariate analysis Multivariate analysis
Hazard ratio P value Hazard ratio
P 
value
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